6533b862fe1ef96bd12c76aa

RESEARCH PRODUCT

New insights into the clinical and molecular spectrum of the novel CYFIP2-related neurodevelopmental disorder and impairment of the WRC-mediated actin dynamics.

Katharina SteindlAlain VerloesCornelia KrausRachel FisherKatrin ÕUnapKatrin ÕUnapAmber BegtrupSteffen SyrbeTheresa BrunetAntonio VitobelloLaurence FaivreReza AsadollahiJessica BeckerMaja HempelDave A DymentDave A DymentChristiane ZweierJohn H McdermottJohn H McdermottBernt PoppBernt PoppElaine Suk-ying GohLynette G. SadleirAnaïs BegemannSiddharth BankaSiddharth BankaGwenaël Le GuyaderElisabeth SchulerAnne-sophie Denommé-pichonKathleen BrownGaetan LescaGaetan LescaFrédéric Tran Mau-themLucia Ribeiro Machado HaertelMaryline CarneiroAmelie Theresa Van Der VenMarkus ZweierHartmut EngelsHeinrich StichtTheresia HergetJessika JohannsenBader AlhaddadNadine N. HauerRobert C. DayTiia ReimandTiia ReimandM. J. HajianpourManuel SchiffManuel SchiffKirsty McwalterMargarita SaenzTatjana BierhalsPierre MeyerAnge-line BruelMartina RussoKorbinian M. RiedhammerKirsten CremerAnita RauchMarjolaine Willems

subject

0301 basic medicine[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyWAVEregulatory complex (WRC)030105 genetics & heredityBiologyArticleIntellectual disability; Epilepsy; CYFIP2; WAVE-regulatory complex (WRC); WASF03 medical and health sciencesNeurodevelopmental disorderSeizuresWAVE-regulatory complex (WRC)medicineCYFIP2Missense mutationHumansGenetics(clinical)WASFGeneGenetics (clinical)ActinAdaptor Proteins Signal TransducingGenetics/dk/atira/pure/subjectarea/asjc/2700/2716medicine.diseaseActin cytoskeletonPhenotypeHypotoniaActins3. Good healthddc:030104 developmental biology[SDV.BDD.EO]Life Sciences [q-bio]/Development Biology/Embryology and OrganogenesisNeurodevelopmental Disordersintellectual disabilityCYFIP2epilepsymedicine.symptom

description

International audience; Purpose: A few de novo missense variants in the cytoplasmic FMRP-interacting protein 2 (CYFIP2) gene have recently been described as a novel cause of severe intellectual disability, seizures, and hypotonia in 18 individuals, with p.Arg87 substitutions in the majority.Methods: We assembled data from 19 newly identified and all 18 previously published individuals with CYFIP2 variants. By structural modeling and investigation of WAVE-regulatory complex (WRC)-mediated actin polymerization in six patient fibroblast lines we assessed the impact of CYFIP2 variants on the WRC.Results: Sixteen of 19 individuals harbor two previously described and 11 novel (likely) disease-associated missense variants. We report p.Asp724 as second mutational hotspot (4/19 cases). Genotype–phenotype correlation confirms a consistently severe phenotype in p.Arg87 patients but a more variable phenotype in p.Asp724 and other substitutions. Three individuals with milder phenotypes carry putative loss-of-function variants, which remain of unclear pathogenicity. Structural modeling predicted missense variants to disturb interactions within the WRC or impair CYFIP2 stability. Consistent with its role in WRC-mediated actin polymerization we substantiate aberrant regulation of the actin cytoskeleton in patient fibroblasts.Conclusion: Our study expands the clinical and molecular spectrum of CYFIP2-related neurodevelopmental disorder and provides evidence for aberrant WRC-mediated actin dynamics as contributing cellular pathomechanism.

10.1038/s41436-020-01011-xhttps://doi.org/10.1038/s41436-020-01011-x